
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Q I have two questions: First, a 17-year-old, well adolescent girl in my practice plucks her eyebrows unknowingly—usually while watching television on school days.






